metaPreg - Albendazole during pregnancy

Albendazole updated on 01-29-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.71 [0.50, 5.82]	0%	2 studies	13	104	not evaluable	ROB	-
Congenital heart defects	-	-	0 study					-
Nervous system anomalies	-	-	0 study					-
Limb defects	-	-	0 study					-
Major congenital malformations	2.20 [0.49, 9.89]	-	1 study	7	64	not evaluable	ROB	-
Minor congenital malformations	1.10 [0.39, 3.11]	-	1 study	18	64	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Jaundice / Icterus	1.10 [0.39, 3.11]	-	1 study	18	64	not evaluable	ROB	-
Neonatal medical care	-	-	0 study					-
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Infant asthma	1.58 [1.13, 2.21]	-	1 study		583	not evaluable	ROB	2.54 [1.51; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	1.41 [0.55, 3.60]	0%	2 studies	22	118	not evaluable	ROB	-
Elective/induced termination of pregnancy	2.82 [0.39, 20.44]	-	1 study	4	70	not evaluable	ROB	-
Intrauterine deaths (as a whole or unspecified)	11.00 [0.16, 780.07]	-	1 study	3	1	not evaluable	ROB	-
Hide endpoints reported in only one study ...